| |
| |
|
| Insider
Information: |
Parker Geoffrey M. |
| Relationship: |
|
| City: |
Carlsbad |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
2,273,914 |
|
|
Indirect Shares
|
410,000 |
|
|
| Direct
Value |
$21,029 |
|
|
|
Indirect Value
|
$537 |
|
|
| Total
Shares |
2,683,914 |
|
|
| Total
Value |
$21,566 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
8
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
8
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-8.0
|
-8.0
|
| Percentage
Gain/Loss : |
 -67.7%
|
-0.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Chemocentryx, Inc. |
CCXI |
Director |
2022-10-20 |
0 |
2022-10-20 |
0 |
Premium* |
|
|
Viracta Therapeutics Ord Shs |
VIRX |
Director |
2016-12-09 |
14,074 |
2016-05-24 |
0 |
Premium* |
|
|
Tricida, Inc. |
TCDA |
COO, CFO and EVP |
2021-12-31 |
63,617 |
2021-12-31 |
356,667 |
Premium* |
|
|
Genomic Health Inc |
GHDX |
Director |
2019-11-08 |
0 |
2019-06-14 |
0 |
Premium* |
|
|
Better Therapeutics |
BTTX |
|
2023-12-18 |
1,031,805 |
2023-12-18 |
53,333 |
Premium* |
|
|
Allogene Therapeutics, Inc. |
ALLO |
|
2024-05-16 |
1,164,418 |
2023-10-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
59 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TCDA |
Tricida, Inc. |
Chief Fin. Officer and Sr. VP |
• – – |
2019-08-13 |
4 |
B |
$32.91 |
$396,302 |
I/I |
11,947 |
30,000 |
1.99 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2022-05-02 |
4 |
OE |
$14.42 |
$180,250 |
D/D |
12,500 |
124,413 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2019-05-30 |
4 |
S |
$12.00 |
$153,806 |
D/D |
(12,815) |
72,199 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2018-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,912 |
58,583 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2015-05-27 |
4 |
AS |
$7.51 |
$101,515 |
D/D |
(13,513) |
13,514 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2013-12-06 |
4 |
B |
$5.15 |
$77,265 |
I/I |
15,000 |
15,000 |
2.1 |
- |
|
| TCDA |
Tricida, Inc. |
CFO and EVP |
• – – |
2020-12-10 |
4 |
B |
$6.78 |
$101,700 |
I/I |
15,000 |
40,000 |
1.99 |
% |
|
| BTTX |
Better Therapeutics |
Director |
– • – |
2022-03-29 |
4 |
B |
$2.15 |
$32,231 |
D/D |
15,000 |
15,000 |
2.39 |
% |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2015-12-10 |
4 |
B |
$7.23 |
$111,202 |
I/I |
15,379 |
34,979 |
2.1 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2019-05-30 |
4 |
OE |
$6.00 |
$108,060 |
D/D |
18,010 |
85,014 |
0 |
- |
|
| TCDA |
Tricida, Inc. |
Chief Fin. Officer and Sr. VP |
• – – |
2019-08-12 |
4 |
B |
$31.64 |
$573,568 |
I/I |
18,053 |
18,053 |
1.99 |
- |
|
| TCDA |
Tricida, Inc. |
Chief Fin. Officer and Sr. VP |
• – – |
2019-11-18 |
4 |
B |
$34.28 |
$653,205 |
I/I |
19,055 |
49,055 |
1.99 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2016-01-11 |
4 |
B |
$4.63 |
$92,512 |
I/I |
20,000 |
59,600 |
2.1 |
- |
|
| TCDA |
Tricida, Inc. |
Chief Fin. Officer and Sr. VP |
• – – |
2019-04-04 |
4 |
A |
$36.00 |
$720,000 |
I/I |
20,000 |
25,000 |
0 |
- |
|
| BTTX |
Better Therapeutics |
Director |
– • – |
2021-12-14 |
4 |
B |
$4.94 |
$98,800 |
I/I |
20,000 |
53,333 |
2.1 |
% |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2017-05-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,362 |
45,671 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
Director |
– • – |
2016-05-25 |
4 |
B |
$0.49 |
$10,933 |
D/D |
22,505 |
52,505 |
2.39 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2022-10-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(26,076) |
0 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2015-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,027 |
27,027 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
CHIEF FINANCIAL OFFICER |
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
29,400 |
819,400 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
Director |
– • – |
2016-05-24 |
4 |
B |
$0.46 |
$13,881 |
D/D |
30,000 |
30,000 |
2.39 |
- |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2020-03-23 |
4 |
S |
$34.43 |
$1,101,049 |
I/I |
(30,000) |
49,600 |
0 |
% |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2021-03-05 |
4 |
S |
$55.89 |
$1,691,468 |
I/I |
(30,000) |
12,690 |
0 |
% |
|
| CCXI |
Chemocentryx, Inc. |
Director |
– • – |
2019-12-02 |
4 |
OE |
$6.00 |
$191,940 |
D/D |
31,990 |
104,189 |
0 |
- |
|
| TCDA |
Tricida, Inc. |
Chief Fin. Officer and EVP |
• – – |
2020-05-11 |
4 |
B |
$29.48 |
$968,437 |
I/I |
32,258 |
92,258 |
1.99 |
% |
|
59 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
